Sonoma Pharmaceuticals opened higher at $1.26, compared with its previous close of $1.24. In the last trading session, the stock traded between $1.15 and $1.27. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Sonoma Pharmaceuticals is now worth
$ 1.02
Resulting in a loss of
$ 98.98 (98.98%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.07 (-5.65%)
Day High
$1.27
Day Low
$1.15
Day Open
$1.26
Prev Close
$1.24
Volume
1,56,381
1W Return
5.88%
1M Return
-6.02%
3M Return
-15.83%
6M Return
0.86%
1Y Return
-68.67%
Fundamentals
Market Cap ($ Mn)
6
PE Ratio
-
PB Ratio
0.96
PEG Ratio
-
ROE
-67.14%
ROCE
-28.57%
EPS (TTM)
$-0.07
Investment Returns
1 Week
5.88%
1 Month
-6.02%
3 Months
-15.83%
6 Months
0.86%
9 Months
-58.95%
Financials
Quarterly
All values in $ Mn
3.8
Mar 25
4.0
Jun 25
5.6
Sep 25
4.3
Dec 25
5.6
Mar 26
6.4
Jun 26
Updates
11Nov
Sonoma Pharmaceuticals Q2 Results: Loss narrows 97% YoY, sales up 28%
Net loss narrowed to $(0.01) per share, a 96.88% improvement YoY. Sales increased 28.02% YoY to $7.174 million. Loss reduction outpaced revenue growth significantly.
2 days ago
1Jul
Sonoma Pharmaceuticals receives FDA 510(k) clearance for Microdacyn
Sonoma Pharmaceuticals received FDA 510(k) clearance for its Microdacyn Wound Irrigation Solution, expanding claims to include multiple use and additional packaging configurations. The solution is indicated for a wide range of wounds and lesions under professional supervision and for over-the-counter management of minor skin issues. The clearance specifically expands the use case to single patient, multiple use.
4mo ago
19Jun
Sonoma Pharmaceuticals increases max offering to $3.64M
Sonoma Pharmaceuticals increased the maximum aggregate offering price of its common stock to $3.64M, as disclosed in a recent SEC filing.
4mo ago
17Jun
Sonoma misses Q4 estimates as sales rise 48% to $5.6 million
Sonoma Pharmaceuticals reported a 48% increase in Q4 FY26 revenue to $5.6 million, driven by US growth, but missed analyst estimates for both sales and EPS. The company reduced its net loss and EBITDA loss for the quarter and full year, while expanding product offerings and regulatory approvals.
